The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection

Kleinman, Steven; Busch, Michael P.; Korelitz, James; Schreiber, George B.

doi:10.1053/tmrv.1997.0110155

Cited by 150 publications

(154 citation statements)

References 44 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…The results of this study are highly dependent on the validity of the assumptions inherent in the mathematical risk model (3,4,8,12,13) and the accuracy of the data used. Musculoskeletal donors are usually only able to donate once during their lifetime, therefore incidence was extrapolated from rates obtained in first-time blood donors.…”

Section: Yao Et Almentioning

confidence: 99%

“…For blood donors, incidence was defined as the number of donors who seroconverted per 100 000 person-years at risk among a group who repeatedly donated blood (12). As described by Seed et al (4), the number of 'person years of observation' was not available necessitating a minor modification to the incidence estimate for donors from the Australian Red Cross Blood Services (ARCBS).…”

Section: Estimated Incidence Of Viral Infections Among Musculoskeletamentioning

confidence: 99%

“…The estimated risk of infectivity-the probability of an undetected window period donation occurring within the study period-was determined by the Incidence/Window Period Model (3,4,8,12,13). This estimate of the residual risk of viral transmission is calculated by assessing the rate of new infection in repeat donors (viral incidence), then multiplying this by the probability of such a donor donating while in the undetectable window period.…”

Section: Estimated Probability Of Viral Infections Among Musculoskelementioning

confidence: 99%

See 2 more Smart Citations

The Risk of HIV, HBV, HCV and HTLV Infection Among Musculoskeletal Tissue Donors in Australia

Yao

Seed

Farrugia³

et al. 2007

American Journal of Transplantation

View full text Add to dashboard Cite

Section: Yao Et Almentioning

confidence: 99%

Section: Estimated Incidence Of Viral Infections Among Musculoskeletamentioning

confidence: 99%

Section: Estimated Probability Of Viral Infections Among Musculoskelementioning

confidence: 99%

See 1 more Smart Citation

The Risk of HIV, HBV, HCV and HTLV Infection Among Musculoskeletal Tissue Donors in Australia

Yao

Seed

Farrugia³

et al. 2007

American Journal of Transplantation

View full text Add to dashboard Cite

“…Therefore, the risks of TTIs are extremely low 3 . It is estimated to be about 1 in 677,000 units of blood for HIV 4 , 1 in 103,000 units for hepatitis C virus and 1 in 63,000 units for hepatitis B virus. 3 Various integrate measures are put in place to make blood transfusion safe.…”

Section: 2mentioning

confidence: 99%

Pre-donation screening of blood for transfusion transmissible infections: The gains and the pains - experience at a resource limited blood bank

Shittu¹,

Olawumi²,

Adewuyi³

2014

Ghana Medical Journal

View full text Add to dashboard Cite

SUMMARYObjective: To determine whether or not pre-donation testing of blood donors affords substantial cost savings without compromise to blood transfusion safety. Predonation testing of blood donors for Transfusion Transmissible Infections (TTIs) is done in most developing countries because substantial cost savings are made from resources, materials and man-hours which would have been spent to procure infected blood units. Simple rapid test kits used in pre-donation testing is not as sensitive as the Enzyme Linked Immuno-sorbent Assay (ELISA) method used in post-donation screening in a quality assured manner. Design: It is a retrospective study where records of pre-and post-donation tests done in donor clinic of University of Ilorin Teaching Hospital, between January and December 2010 were retrieved. All processes and inputs were evaluated and costs calculated for predonation testing by simple rapid techniques and post donation screening by ELISA. Results: 5000 prospective donors were tested in the study period. The cost of single rapid Pre-donation testing was less than that of single ELISA Postdonation screen. The cost of double rapid Pre-donation and Post donation ELISA screen exceeded the cost of single post donation ELISA screen. Substantial cost savings were made when single rapid Pre-donation testing is relied on. More blood units were found reactive for the TTIs with the more expensive Postdonation ELISA. Conclusion: Pre-donation testing of blood donors was not cost effective. Although, there is an apparent savings if pre-donation testing is not followed by postdonation ELISA testing, it is done at a compromise to blood transfusion safety.

show abstract

“…A study carried out by Donahue et al (1992) demonstrated that before the introduction of the first assay for anti-HCV detection in 1990, the risk of transmission for each unit of blood transfused was 0.45%, while the implementation of this technique lowered the risk to 0.03%. The risk of transmission was further reduced following the introduction of second and third generation assays in 1992 and 1996, respectively (Kleiman et al 1997, Stramer et al 1998.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of five screening tests licensed in Argentina for detection of hepatitis C virus antibodies

Ré¹,

Gallego²,

Treviño

et al. 2005

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection

Cited by 150 publications

References 44 publications

The Risk of HIV, HBV, HCV and HTLV Infection Among Musculoskeletal Tissue Donors in Australia

The Risk of HIV, HBV, HCV and HTLV Infection Among Musculoskeletal Tissue Donors in Australia

Pre-donation screening of blood for transfusion transmissible infections: The gains and the pains - experience at a resource limited blood bank

Evaluation of five screening tests licensed in Argentina for detection of hepatitis C virus antibodies

Contact Info

Product

Resources

About